Cargando…

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor

Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in English-language journals is less than 30. Due to this extremely low incidence, no specific treatment guidelines have been established, and most of what is clinically known is derived from a handful of sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brzezniak, Christina, Oronsky, Bryan, Trepel, Jane, Summers Jr., Thomas A., Cabrales, Pedro, Lee, Min-Jung, Day, Regina, Jha, Saheli, Caroen, Scott, Zeman, Karen, Ferry, Lindsey, Harmer, Cindy, Oronsky, Neil, Lybeck, Michelle, Lybeck, Harry E., Brown, James F., Reid, Tony R., Carter, Corey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422722/ https://www.ncbi.nlm.nih.gov/pubmed/28512410 http://dx.doi.org/10.1159/000464101

Ejemplares similares

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001
por: Oronsky, Bryan, et al.
Publicado: (2016)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
por: Carter, Corey A., et al.
Publicado: (2016)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
por: Jani, Vinay P., et al.
Publicado: (2021)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2016)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

No patient left behind: The promise of immune priming with epigenetic agents
por: Carter, Corey A., et al.
Publicado: (2017)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
por: Jayabalan, Nanthini, et al.
Publicado: (2023)

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome
por: Brzezniak, Christina E., et al.
Publicado: (2017)

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
por: Yalcin, Ozlem, et al.
Publicado: (2015)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
por: Carter, Corey A., et al.
Publicado: (2016)

The War on Cancer: A Military Perspective
por: Oronsky, Bryan, et al.
Publicado: (2015)

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report
por: Oronsky, Neil, et al.
Publicado: (2017)

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
por: Zhao, Hongjuan, et al.
Publicado: (2015)

Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001
por: Hammond, Terese Catherine, et al.
Publicado: (2022)

RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice
por: Jurgensen, Kimberly J., et al.
Publicado: (2021)

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016)

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
por: Tomita, Yusuke, et al.
Publicado: (2021)

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7blei8sla3b3shlpq3ss4gp1c8